FLT3 and acute myeloid leukemia: FLT3 with internal tandem duplications within the juxtamembrane domain (FLT3-ITD) is present in 20–30% of AML patients, and a missense mutation in the tyrosine kinase domain (FLT3-TKD) accounts for about 10% of AML [4, 5].